Trial
NCT04644029
Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Merck Sharp & Dohme LLC
Collaborators
—
Condition
HIV-I
Intervention
Islatravir
Why stopped
Voluntarily terminated due to benefit/risk assessment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-02-04